BarbriSFCourseDetails
  • videocam On-Demand
  • card_travel Patent
  • schedule 90 minutes

Antibody Patenting: U.S. and Asian Perspectives

Meeting Patentability Requirements in the USPTO, JPO, and CNIPA

$347.00

This course is $0 with these passes:

CLE
ALL
  1. keyboard_arrow_leftBack
BarbriPdBannerMessage

Description

Patent applicants frequently employ functional claims to provide broad protection for antibody inventions. However, the Amgen v. Sanofi decision from the Federal Circuit called into question the USPTO's practice of granting claims that define antibodies by their ability to bind to a newly characterized antigen.

Unlike the decision in Amgen, Japan and China will grant a patent for an antibody without producing an actual antibody, provided the antigen is structurally described and has some function.

To meet the support requirements, the JPO requires that the specification describe actual data relating to a claimed use. Japanese law does not permit post-filing data showing such activity to overcome a rejection if the specification does not include any data on activity. Chinese support and disclosure requirements are similar.

To obtain a granted claim on a new antibody to a known antigen, all jurisdictions generally require defining and claiming the antibody structurally. Japanese (JPO) and Chinese examiners (CNIPA) typically require the inclusion of the sequences of the antibody's six complementarity determining regions when claiming an antibody. Furthermore, outside the U.S., structural non-obviousness per se may be insufficient to claim an antibody even if defined by sequence, and it may be necessary to demonstrate that the antibody produces an unexpected technical effect or was produced using non-conventional techniques.

Listen as our authoritative panel of patent attorneys provides guidance on protecting design rights in the global marketplace. The panel will discuss the key differences between the patent laws in the U.S. and other countries that must be understood when developing a strong global IP strategy. The panel will offer best practices for U.S. companies on developing a global strategy.

Presented By

Jeffrey M. Jacobstein
Partner
Finnegan Henderson Farabow Garrett & Dunner LLP

Mr. Jacobstein focuses on strategic client counseling, including due diligence, patent prosecution, and post-grant proceedings, with an emphasis on biotechnology and the life sciences. His experience includes prosecuting and appealing applications within the USPTO, as well as post-grant proceedings and larger portfolio management, licensing, and opinion work. He has conducted numerous evaluations for diligence, clearance, and freedom-to-operate assessments, and has extensive experience providing patentability, validity, enforceability, and infringement opinions.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Daniel Miao Cheng
Director, Founding Partner
Cheng & Peng

Mr. Miao Cheng is an experienced Chinese patent attorney and has been practicing Chinese law for 16 years. His practice area includes patent infringement litigation, patent administrative litigation, patent invalidation, patent drafting and prosecution, licensing and transaction, FTO, due diligence, and legal opinions; trademark prosecution, opposition, invalidation and licensing. He has represented Pfizer, Roche, Eli Lilly, AstraZeneca, Novo Nordisk, Bayer, Merck, Wyeth, Ajinomoto, among others in patent litigation.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Amanda K. Murphy
Partner
Finnegan Henderson Farabow Garrett & Dunner LLP

Dr. Murphy focuses her practice on client counseling and patent prosecution for a range of clients. She prepares new patent applications, prosecutes U.S. and foreign applications, and represents applicants at appeals and oral hearings before the PTAB. She has experience in prosecuting inter partes and ex partes reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Osamu Yamamoto
Partner, Patent Division, Chief of Chemical Section
YUASA And HARA

Mr. Yamamoto is an experienced patent attorney. He has 10 years of experience in biotechnology and pharmaceutical research at a chemical company before specializing in intellectual property. He has represented a variety of companies in the fields of food and beverages, diagnostics, biotechnology and pharmaceuticals. He is experienced in patent prosecution, invalidation trials and infringement lawsuits.

expand_circle_down Expand to View Full Bio expand_circle_up Collapse Bio
Credit Information

  • This 90-minute webinar is eligible in most states for 1.5 CLE credits.


  • Live Online


    On Demand

Date + Time

  • event

    Thursday, September 10, 2020

  • schedule

    1:00 p.m. ET./10:00 a.m. PT

  1. Written description requirements for antibody claims
  2. Obviousness requirements for antibody claims
  3. Case law developments
  4. How examiners are instructed to assess antibody claims
  5. How to best protect antibodies globally and how broadly claims should be drafted
  6. How to provide disclosure and data in a patent application to support different claim strategies

The panel will review these and other relevant issues:

  • How broadly can the applicant claim? How much support is needed on a filing?
  • What are the differences between U.S. requirements, JPO requirements, and CNIPA requirements?
  • What is a sufficient description of a genus? Can functional language be included?
  • When can post-filing data be used?
  • What is needed to demonstrate the nonobviousness of antibody claims in different jurisdictions?